Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1E | P28566 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553914 | 0.94 | HTR6 (0.49) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3568540 | 0.93 | HTR6 (0.40) | HTR6ACLYHTR1ADRD2HTR1D | |
| SCHEMBL3927118 | 0.92 | ACLY (0.44) | HTR6ACLYHTR1ADRD2HTR1D | |
| SCHEMBL3553338 | 0.90 | HTR6 (0.45) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3556831 | 0.90 | HTR6 (0.44) | HTR6ACLYHTR1ADRD2HTR1D | |
| SCHEMBL3560055 | 0.88 | HTR6 (0.48) | HTR6 | |
| SCHEMBL3563161 | 0.87 | HTR6 (0.38) | HTR6ACLYHTR1ADRD2HTR1D | |
| SCHEMBL3556528 | 0.86 | HTR6 (0.53) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3554463 | 0.86 | PTPN1 (0.39) | HTR6ACLYHTR1ADRD2HTR1D | |
| SCHEMBL3556962 | 0.85 | HTR6 (0.47) | HTR6ACLYHTR1ADRD2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | claimed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | claimed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| EP-1567492-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | Suven Life Sciences Limited (IN) | 2005-08-31 | — | — | EP | claimed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | claimed |
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| CN-102292826-A | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | — | 2011-12-21 | — | — | CN | disclosed |
| CN-102245581-A | Tetrahydrotriazine compounds for the treatment of diseases which are associated with AMPK activity | POXEL | 2011-11-16 | — | — | CN | disclosed |
| CN-101932566-A | Process for preparing 3, 6-dihydro-1, 3, 5-triazine derivatives | POXEL SAS | 2010-12-29 | — | — | CN | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | disclosed |
| CN-100383130-C | Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome. | MERCK PATENT GMBH (DE) | 2008-04-23 | — | — | CN | disclosed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| CN-1771233-A | Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome. | MERCK PATENT GMBH (DE) | 2006-05-10 | — | — | CN | disclosed |
| EP-1574503-A1 | NOVEL 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVE | Hamari Chemicals Co., Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| EP-1567492-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | Suven Life Sciences Limited (IN) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | HTR6 56/4885ACLY 4542/4885HTR1A 20/4885 |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | HTR6 56/4885ACLY 4542/4885HTR1A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.